Caption Management’s Karyopharm Therapeutics KPTI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$42.7K Sell
35,000
-250,700
-88% -$1.03M ﹤0.01% 1672
2026
Q2
$2.79M Sell
285,700
-801,200
-74% -$6.95M 0.01% 789
2026
Q1
$6.05M Buy
+1,086,900
New +$8.29M 0.04% 479
2021
Q3
– Sell
-5,333
Closed -$826K – 1649
2021
Q2
$826K Buy
+5,333
New +$774K 0.01% 944
2020
Q2
– Sell
-6,000
Closed -$1.73M – 1084
2020
Q1
$1.73M Buy
6,000
+2,333
+64% +$644K 0.1% 288
2019
Q4
$1.05M Buy
3,667
+2,667
+267% +$579K 0.04% 498
2019
Q3
$144K Sell
1,000
-5,667
-85% -$768K 0.01% 616
2019
Q2
$599K Buy
+6,667
New +$535K 0.03% 455

Other funds holding KPTI

Caption Management's KPTI Position: Q3 2026 in Review

Caption Management opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2026: 185,745 shares worth $227K. The stake represents ﹤0.01% of the portfolio and ranks #1558 among its holdings. This is a return to the name: Caption Management previously reported a position in KPTI as recently as Q2 2020.

Caption Management first reported a position in KPTI in Q2 2019 and has held it in 3 quarters since. The position peaked at $379K in Q2 2020. 92 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

  • Caption Management held 185,745 shares of Karyopharm Therapeutics worth $227K as of Q3 2026.
  • Karyopharm Therapeutics was a new Caption Management position in Q3 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q3 2026, its #1558 holding.
  • Caption Management first reported a position in Karyopharm Therapeutics in Q2 2019 and has held it in 3 quarters since.
  • Caption Management's Karyopharm Therapeutics position peaked at $379K in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on Caption Management's 13F filing for Q3 2026, filed 16 Nov 2026.